Page 1 of 1

The Use of Dapsone as a Novel “Persister” Drug in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Synd

Posted: Fri 22 Apr 2016 13:35
by ChronicLyme19 ... 000345.pdf

The Use of Dapsone as a Novel “Persister” Drug in the Treatment of Chronic
Lyme Disease/Post Treatment Lyme Disease Syndrome
Horowitz and Freeman, J Clin Exp Dermatol Res
2016, 7:3

Dapsone (diaminodiphenyl sulfone, i.e., DDS) is commonly used to treat dermatological conditions including
acne, dermatitis herpetiformis, and leprosy. Mycobacterium leprae, a known "persister" bacteria, requires long-term
treatment with intracellular medications including rifampin and Dapsone. Other "persister" bacteria recently have
been identified, including Borrelia burgdorferi, the agent of Lyme disease.

Objectives: We tested the efficacy of DDS in patients with chronic Lyme disease/PTLDS with tick-borne coinfections including Babesiosis, who failed commonly used antibiotic and antimalarial protocols.

Methods: 100 patients with Lyme disease, 56 of who were Babesia positive, were placed on Dapsone and folic
acid in combination with either one or two other intracellular drugs, including rifampin, tetracyclines, and/or macrolide antibiotics. Several patients also took cephalosporins, and all patients were on protocols to treat cystic forms of Borrelia and biofilms.

Results: Patients completed a symptom severity survey before beginning treatment with Dapsone and then
again after at least one month of treatment scoring their complaints from 0 indicating “none” to 4 indicating “severe” for symptoms including fatigue, joint and/or muscle pain, disturbed sleep, and cognitive difficulties. Results demonstrated that Dapsone significantly improved all patients’ clinical symptoms except for headache, where
changes did not reach statistical significance. In addition, Dapsone, known to have anti-malarial effects, helped
resistant Babesia symptoms of sweats, chills, and flushing. Lyme positive, Babesia positive patients also
demonstrated significant changes in pain, disturbed sleep, and cognitive difficulties. Side effects included macrocytic anemia and rare cases of methemoglobinemia, which resolved by either decreasing the dose of Dapsone or increasing folic acid.

Conclusion: Dapsone is a novel and effective “persister” drug for those with PTLDS and associated tick-borne
co-infections who have failed classical antibiotic protocols. Further prospective trials must determine the [/url]